Light or Heavy Chain Deposition Disease
(LCDD, HCDD)

Article written and reviewed by Dr Luca Moretti

Light Chain Deposition Disease (LCDD) and Heavy Chain Deposition Disease (HCDD) are rare systemic plasma cell dyscrasias characterized by nonfibrillar tissue deposition of monoclonal immunoglobulins or their fragments, consisting respectively of light chains in Light Chain Deposition Disease or heavy chains in Heavy Chain Deposition Disease.

These disorders belong to the group of monoclonal immunoglobulin deposition diseases and are clearly distinguished from amyloidoses by the absence of fibrillar organization of the deposited proteins and by different histochemical, structural and staining properties, including absence of apple-green birefringence under polarized light after Congo red staining.

In LCDD, deposits consist predominantly of kappa light chains produced in excess by a pathologic plasma-cell clone or, less frequently, by B lymphocytes. HCDD is instead characterized by accumulation of abnormal fragments of gamma, alpha or, more rarely, mu heavy chains. In both forms, monoclonal immunoglobulins deposit in a nonorganized pattern along basement membranes in several organs, particularly the kidney, although the liver, heart and other sites may also be involved.

The disease occurs mainly in adulthood. The population incidence of LCDD and HCDD is not precisely defined; HCDD is markedly rarer than LCDD. Both may be underdiagnosed because of their subtle clinical presentation and resemblance to other glomerular or systemic nephropathies.

Renal involvement is nearly constant in LCDD, whereas the clinical picture of HCDD can be more variable. Diagnostic delay is common in both disorders and may have serious prognostic consequences because of progression to organ failure and possible coexistence or progression of the underlying B-cell or plasma-cell clone.

Etiology, pathogenesis and pathophysiology

The etiology of Light Chain Deposition Disease (LCDD) and Heavy Chain Deposition Disease (HCDD) lies in abnormal production of monoclonal immunoglobulins, respectively light chains, predominantly kappa, and heavy chains, usually gamma and occasionally alpha or mu, by neoplastic plasma-cell clones in the bone marrow. More rarely, deposits may derive from abnormal immunoglobulins secreted by malignant B lymphocytes.

In LCDD, the plasma-cell clone may be small or may occur in the setting of multiple myeloma or other plasma-cell or lymphoproliferative dyscrasias; when a small clone causes deposition and renal injury, the condition falls within MGRS rather than asymptomatic MGUS. HCDD, which is much rarer, may be associated with a plasma-cell or B-cell clone, while in some cases no overt hematologic neoplasm is identified.

No specific environmental or immunologic risk factors have been defined for LCDD or HCDD. The predisposing setting is the presence of a monoclonal clone, which becomes more frequent with age; structural properties of the monoclonal protein contribute to deposition, but no necessary and universal set of molecular abnormalities has been established.

From a pathogenetic standpoint, the central mechanism is excessive secretion of abnormal kappa light chains in LCDD or incomplete heavy chains in HCDD, with structural characteristics that favor binding to basement membranes and other components of the extracellular matrix. These molecules often contain mutations in variable and constant domains that alter solubility, resistance to proteolytic degradation and propensity to aggregate, without acquiring the typical fibrillar organization of amyloid.

In LCDD, kappa light chains deposit predominantly in glomerular, tubular and vascular basement membranes of the kidney, but also in other sites such as liver, heart, lungs and peripheral nerves, in granular or amorphous form. In HCDD, heavy-chain fragments, often lacking the CH1 domain that is essential to normal immunoglobulin structure, tend to accumulate in the same locations, producing similar histochemical and ultrastructural patterns with possible extrarenal deposition.

From a pathophysiologic standpoint, deposition of monoclonal immunoglobulins in basement membranes causes profound structural and functional abnormalities. In the kidney, dense nonorganized deposits lead to thickening of glomerular basement membranes, podocyte injury, mesangial proliferation and progressive glomerulosclerosis, with consequent nephrotic-range proteinuria, loss of filtration capacity and development of rapidly progressive chronic kidney disease.

Other organs may also be affected. In the heart, deposits cause endocardial thickening, interstitial fibrosis and impaired diastolic function, producing a clinical picture that may mimic restrictive cardiomyopathy. In the liver, hepatomegaly and abnormal liver function may occur and, in advanced disease, signs of portal hypertension may develop. Infiltration of blood vessels and capillaries contributes to arterial hypertension and worsening organ dysfunction.

Unlike amyloidosis, the morphology of deposits in LCDD and HCDD is typically granular and nonfibrillar and is Congo-red negative. Deposits are demonstrated primarily by immunofluorescence for light or heavy chains, with immunohistochemistry serving as a complementary method. Their nonfibrillar nature and preferential distribution along basement membranes produce a distinct clinical and morphologic pattern that is fundamental to the differential diagnosis.

The clinical variability of these disorders is determined by the amount of pathologic immunoglobulin production, its tissue affinity and individual susceptibility of different organs to accumulation and deposit-mediated injury. These aspects are reflected in the clinical manifestations described below.

Clinical manifestations

The clinical presentation of Light Chain Deposition Disease (LCDD) and Heavy Chain Deposition Disease (HCDD) is extremely heterogeneous and depends on the site, extent and rate of deposition of pathologic immunoglobulins. In both forms, renal involvement is the principal manifestation and often the route to diagnosis, although disease may extend to other organs and form a systemic spectrum.

In the kidney, typical onset consists of proteinuria of variable severity, often in the nephrotic range (>3.5 g/day), accompanied by peripheral edema, hypoproteinemia, hypercholesterolemia and progressive decline in renal function. Proteinuria may be isolated initially but frequently progresses to overt nephrotic syndrome and rapidly progressive chronic kidney disease, often refractory to conventional therapy. Physical examination may reveal dependent edema, weight gain and, in advanced cases, signs of uremia.

In more severe cases or when production of pathologic immunoglobulin is high, progression to end-stage renal disease may be rapid and dialysis may be required early. In some patients, the diagnosis is established only after renal replacement therapy has begun, following retrospective histologic investigations.

Extrarenal involvement is more variable and less constant than in AL amyloidosis, but may affect several organs:

In the heart, light- or heavy-chain deposits cause thickening of ventricular walls and valves, interstitial fibrosis and impaired myocardial compliance, leading to restrictive cardiomyopathy. Symptoms include exertional dyspnea, orthopnea, peripheral edema, palpitations and, in advanced cases, congestive heart failure. Involvement of the conduction system may cause arrhythmias and rhythm disturbances with risk of syncope and sudden death.

The liver may be involved, with hepatomegaly, abnormal liver-function indices, particularly elevated alkaline phosphatase, rare jaundice and, in more severe forms, signs of portal hypertension such as ascites, splenomegaly and esophageal varices. The liver may be firm, painless and palpable below the costal margin.

The peripheral nervous system is involved only in a minority of cases, with manifestations including distal sensorimotor polyneuropathy, paresthesias, hypoesthesia, muscle weakness and, occasionally, autonomic neuropathy with orthostatic hypotension, sphincter dysfunction and sweating abnormalities.

Other possible sites of deposition include the lung, with pleural effusions and dyspnea, the skin, with thickening, plaques or nodules, the gastrointestinal tract, with malabsorption, diarrhea and weight loss, and blood vessels, with possible development of secondary arterial hypertension due to direct vascular injury.

Some patients have a monosymptomatic presentation, for example isolated proteinuria or nonspecific symptoms such as worsening fatigue, weight loss, generalized edema, malabsorption syndrome, joint pain and laboratory abnormalities of uncertain interpretation.

Overall, the clinical picture is often subtle and insidious in the early stages, causing even prolonged diagnostic delays. However, rapid progression to organ failure, particularly renal failure, and the risk of severe systemic complications require a high level of clinical suspicion whenever a monoclonal gammopathy is associated with nephropathy not otherwise explained.

Investigations and diagnosis

The diagnosis of light or heavy chain deposition disease (LCDD, HCDD) is a significant clinical challenge because of the subtle presentation and frequent overlap with other nephropathies and plasma cell dyscrasias.

Suspicion should arise in the presence of progressive nephrotic-range proteinuria, progressive renal failure and systemic signs, particularly in older adults with a known or suspected monoclonal gammopathy. Timely recognition is essential to prevent irreversible loss of organ function.

The diagnostic pathway begins with routine laboratory tests, which may reveal significant proteinuria, hypoalbuminemia, worsening renal failure, hypercholesterolemia and anemia.
Detection of the monoclonal component relies on serum and urine electrophoresis and immunofixation, together with measurement of serum free light chains and the kappa/lambda ratio.
When HCDD is suspected, targeted immunofixation is performed to detect abnormal heavy-chain components. These tests can document a monoclonal gammopathy even in the absence of overt myeloma.

Renal biopsy is the diagnostic gold standard: it identifies dense, granular, nonfibrillar deposits located predominantly in glomerular, tubular and vascular basement membranes.
These deposits are characteristically Congo-red negative and lack apple-green birefringence under polarized light, while showing strong monoclonal light-chain staining in LCDD or heavy-chain staining in HCDD by immunofluorescence, with immunohistochemistry as a complementary technique.

For a definitive diagnosis of LCDD or HCDD, the following clinicopathologic diagnostic requirements must be met:

• Presence of granular nonfibrillar deposits in glomerular, tubular or vascular basement membranes, demonstrated on renal biopsy or biopsy of another involved organ;
• Negative Congo-red staining and absence of apple-green birefringence under polarized light;
• Immunohistochemical or immunofluorescent identification of monoclonal light chains (kappa or lambda) or heavy chains within the deposits;
• Search for the monoclonal component in blood and urine and characterization of the clone; the circulating protein may nevertheless be undetectable by standard tests, while the diagnosis remains based on tissue demonstration of monoclonal deposits;
• Exclusion of other causes of glomerular nephropathy and systemic amyloidosis.

Electron microscopy confirms the amorphous, nonfibrillar nature of deposits and is essential in uncertain cases or when concomitant amyloidosis is suspected. When extrarenal involvement is present, biopsy of the liver, heart or other tissues may provide additional supportive evidence.

The bone marrow is examined by aspiration and biopsy to detect even minimal plasma-cell or lymphocytic infiltration, while cytogenetic and molecular studies contribute to prognostic and therapeutic stratification.

Imaging investigations, including renal ultrasound, echocardiography, cardiac magnetic resonance imaging and liver ultrasound, are used to define the extent of organ involvement and monitor disease progression.

The differential diagnosis includes other glomerulonephritides, including membranous and membranoproliferative patterns and focal segmental glomerulosclerosis, diabetic nephropathy and especially systemic amyloidoses. Only integration of clinical, laboratory and histologic data allows LCDD/HCDD to be distinguished from these conditions and permits accurate classification and timely targeted treatment.

Diagnostic timeliness is crucial to clinical outcome: progression to end-stage renal disease or multiorgan involvement may be rapid and irreversible, which is why high clinical suspicion must be maintained in patients with a monoclonal gammopathy and an atypical renal presentation.

Treatment and prognosis

The treatment of Light Chain Deposition Disease (LCDD) and Heavy Chain Deposition Disease (HCDD) aims primarily to suppress the plasma-cell or B-cell clone responsible for production of pathologic immunoglobulins, halt progression of tissue deposition and preserve, as far as possible, compromised organ function. Treatment is complex and must be individualized according to age, overall clinical status, extent of organ damage and the type of clone involved.

Clone-directed therapy is selected according to the clone and organ function. In plasma-cell forms, regimens based on bortezomib and dexamethasone, with additional agents when appropriate, are frequently used; daratumumab may be considered in selected cases on the basis of evidence that remains more limited than that supporting established multiple myeloma standards.

Autologous stem cell transplantation may be considered in selected eligible patients and is not a universally appropriate choice. It can produce deep and durable remissions but is reserved for a minority because of the high risk of toxicity in patients with advanced organ dysfunction.

In patients who are not transplant candidates, conventional chemotherapy regimens are used with particular attention to tolerability and prevention of infectious and hematologic complications. Lenalidomide or pomalidomide may be considered in disease resistant to first-line treatment, in combination with dexamethasone and other agents.

Supportive therapies are essential and include management of renal failure, with control of fluid and electrolyte balance, treatment of nephrotic syndrome and hypertension and dialysis when required; prevention of infections; protection of cardiac function, including cautious diuretic use and management of heart failure and arrhythmias; nutritional support; and treatment of symptoms related to involvement of other organs.

No approved therapy can directly remove LCDD or HCDD deposits. The therapeutic strategy therefore consists of suppressing the responsible clone and treating organ damage; approaches aimed at clearance of deposits remain experimental and are not a clinical standard.

Follow-up of patients with LCDD/HCDD requires careful monitoring of hematologic response, including serum light chains, immunofixation and assessment of the marrow clone, together with organ function, including glomerular filtration, proteinuria, markers of organ damage and cardiac and hepatic imaging. A complete or very good hematologic response is associated with a greater probability of renal recovery and long-term survival, whereas a partial or absent response implies a poorer prognosis.

The prognosis is closely related to the extent and rate of organ involvement, especially renal and cardiac, the therapeutic response and the timeliness of diagnosis. In patients with advanced renal failure, median survival is significantly reduced, although therapeutic advances have improved quality and duration of life in patients who achieve a deep and stable hematologic response.

Kidney transplantation may be considered in selected cases when hematologic remission is stable and there is no progression of the neoplastic clone, but the risk of recurrence in the graft remains high if the underlying disease is not completely controlled.

In conclusion, effective treatment of LCDD and HCDD is based on multidisciplinary management involving hematologists, nephrologists, cardiologists and other specialists, with the aim of controlling the underlying disease, preventing progression of organ lesions and improving the patient's overall prognosis.

Complications

The complications of Light Chain Deposition Disease (LCDD) and Heavy Chain Deposition Disease (HCDD) are numerous and are central determinants of prognosis and quality of life. They result from progressive accumulation of monoclonal immunoglobulins in tissues, the consequent structural and functional damage, and adverse effects of antineoplastic and supportive therapies.

The most frequent and feared complication is end-stage chronic kidney disease, which may result from progressive glomerulosclerosis, loss of filtration function and persistent massive proteinuria. Progression to dialysis dependence may be rapid, particularly when diagnosis is delayed and therapeutic response is inadequate. Renal-failure complications include electrolyte disturbances, hyperkalemia, metabolic acidosis, secondary hyperparathyroidism, anemia and mineral-bone metabolism disorders.

When the heart is involved, immunoglobulin deposits cause thickening and stiffness of myocardial walls, leading to restrictive cardiomyopathy, heart failure, arrhythmias and conduction blocks. Involvement of the electrical conduction system may cause syncope and increase the risk of sudden death. Secondary heart failure significantly reduces survival, especially in patients who do not respond to hematologic therapy.

If involved, the liver may develop hepatomegaly, progressive hepatic dysfunction, impaired synthesis of coagulation factors and portal hypertension with ascites and risk of gastrointestinal bleeding. Coagulopathy is often worsened by the nephrotic state and loss of plasma proteins.

Neurologic complications include sensorimotor polyneuropathy, muscle weakness, loss of functional independence and autonomic neuropathy with orthostatic hypotension and intestinal motility disorders. In severe cases, neuropathy may impair swallowing, continence and blood-pressure regulation, increasing overall morbidity.

Skin and soft-tissue involvement may cause thickening, plaques, nodules, swelling and, rarely, ulcerative lesions or recurrent infections. Blood-vessel involvement may promote resistant arterial hypertension and increase the risk of thromboembolic events.

Hematologic and systemic complications include anemia, recurrent infections due to iatrogenic immunosuppression or the disease itself, and leukopenia and thrombocytopenia related to chemotherapy. Neutropenia increases the risk of sepsis, pneumonia, urinary tract infections and opportunistic infections, especially in patients undergoing autologous stem cell transplantation.

Disease relapse and treatment resistance are major adverse events: renewed production of pathologic immunoglobulins, evolution of the neoplastic clone and loss of treatment efficacy are principal causes of therapeutic failure and worsening prognosis. Management of relapse requires salvage strategies that are often less effective and more toxic than first-line treatment.

Iatrogenic complications related to chemotherapy, immunosuppression and transplantation include bone marrow toxicity, cytopenias, organ toxicity, opportunistic infections, allergic reactions and risk of secondary malignancies. Management must always balance efficacy and tolerability, particularly in frail patients.

Finally, psychosocial complications, including anxiety, depression, loss of independence and social isolation, are common and often underestimated but substantially affect quality of life and adherence to treatment, requiring integrated multidisciplinary support.

Management of complications, together with control of the pathologic clone, is a cornerstone of comprehensive care for patients with LCDD or HCDD, with the goal of prolonging survival and improving both organ function and quality of life.

References
1. Nasr SH et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clinical Journal of the American Society of Nephrology. 7, 2, 2012, 231-239.
2. Leung N et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 120, 22, 2012, 4292-4295.
3. Bridoux F et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney International. 87, 4, 2015, 698-711.
4. Kanzaki G et al. Monoclonal Immunoglobulin Deposition Disease and Related Diseases. Journal of Nippon Medical School. 86, 1, 2019, 2-9.
5. Lin J et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. Journal of the American Society of Nephrology. 12, 7, 2001, 1482-1492.
6. Pozzi C et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. American Journal of Kidney Diseases. 42, 6, 2003, 1154-1163.
7. Ronco PM et al. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. Journal of the American Society of Nephrology. 12, 7, 2001, 1558-1565.
8. Joly F et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 133, 6, 2019, 576-587.
9. Cohen C et al. Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management. Diagnostics. 11, 3, 2021, 420.
10. Zhang Y et al. Heavy Chain Deposition Disease: Clinicopathologic Characteristics of a Chinese Case Series. American Journal of Kidney Diseases. 75, 5, 2020, 736-743.